Simon J Howard on Muck Rack

Simon J Howard

Newcastle upon Tyne
As seen in: Nature, Memory Studies, Which? Conversation, Raconteur, Responsible Investor, Who Do You Think You Are?
I'm not twittering any more, but sometimes auto-post things from elsewhere. I don't see @ messages or DMs so don't think you're just being ignored! :-)
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Simon J

Contact Simon J, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Daraxonrasib Doubles Survival in Pancreatic Cancer at ASCO

|
By Simon J Howard, Louise Howard
| lifesciencedaily.news
When Brian Wolpin, Professor of Medicine at Harvard Medical School and Director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, advanced to the next slide during the plenary session at the 2026 ASCO (American Society of Clinical Oncology) Annual Meeting in Chicago, May 29 to June 2, 2026, the audience of oncology professionals fell silent.
Open in Who Shared Issue with article?

Weekly News Roundup | 8 June 2026

|
By Simon J Howard, Louise Howard
| lifesciencedaily.news
Life science news 8 June 2026: ASCO delivers landmark oncology data, GSK achieves hepatitis B functional cure breakthrough, and Servier secures a $2.65 billion rare disease deal in a milestone week for the industry. Revolution Medicines presented full Phase 3 data for daraxonrasib at ASCO 2026, with simultaneous publication in the New England Journal of Medicine, building on top-line results first reported in May.
Open in Who Shared Issue with article?

Biosimilar Approvals 2026: What’s Approved and What’s Next

|
By Simon J Howard, Louise Howard
| lifesciencedaily.news
The biosimilar market in 2026 is delivering on years of regulatory groundwork, and the numbers tell a striking story. Since the first US biosimilar was approved in 2015, the sector has generated more than $56 billion in healthcare savings, according to Cardinal Health’s 2026 Biosimilars Report. Today, with 86 products cleared by the FDA and a pipeline rich in high-value targets, the pace is not slowing.
Open in Who Shared Issue with article?
See all 63 licensed articles (65 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Simon J

Contact Simon J, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified